infused CD22 CAR T cells into 20 R/R B-ALL patients in CR when the first infusion of CD19 CAR T cells was undetectable, with a median interval of two CAR T cell infusions of 1.65 months. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.